Assignee
TERNS PHARMACEUTICALS INC
US·13 granted patents·23 pending applications·20 citations·filing 2018–2025
Top patents by PatentIndex Score
36 records- 0196US12378239B2Compounds as GLP-1R agonistsTERNS PHARMACEUTICALS INC·Filed 2025·Granted Aug 5, 2025·1 cites·20 claims
- 0296US12378237B2Compounds as GLP-1R agonistsTERNS PHARMACEUTICALS INC·Filed 2025·Granted Aug 5, 2025·1 cites·20 claims
- 0396US12378236B2Compounds as GLP-1R agonistsTERNS PHARMACEUTICALS INC·Filed 2025·Granted Aug 5, 2025·1 cites·20 claims
- 0496US12378238B2Compounds as GLP-1R agonistsTERNS PHARMACEUTICALS INC·Filed 2025·Granted Aug 5, 2025·1 cites·20 claims
- 0596US12024507B2Compounds as GLP-1R agonistsTERNS PHARMACEUTICALS INC·Filed 2022·Granted Jul 2, 2024·14 cites·32 claims
- 0692US12240835B2Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activityTERNS PHARMACEUTICALS INC·Filed 2023·Granted Mar 4, 2025·1 cites·4 claims
- 0789US12410163B2Compounds as GLP-IR agonistsTERNS PHARMACEUTICALS INC·Filed 2023·Granted Sep 9, 2025·1 cites·23 claims
- 0886US2025282772A1Compounds as glp-1r agonistsTERNS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0980US2023150998A1Compounds as glp-1r agonistsTERNS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1080US2024316025A1Combination treatment of liver disordersTERNS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1178US12454524B2(r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemiasTERNS PHARMACEUTICALS INC·Filed 2025·Granted Oct 28, 2025·0 cites·30 claims
- 1277US12522596B2Compounds as GLP-1R agonistsTERNS PHARMACEUTICALS INC·Filed 2025·Granted Jan 13, 2026·0 cites·20 claims
- 1377US12486261B2Compounds as GLP-1R agonistsTERNS PHARMACEUTICALS INC·Filed 2024·Granted Dec 2, 2025·0 cites·46 claims
- 1476US2025099468A1Treating liver disorders with an ssao inhibitorTERNS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1575US2024000765A1Combination treatment of liver disordersTERNS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1674US2025276961A1Compounds for treating certain leukemiasTERNS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1769US2023181583A1Treating liver disorders with an ssao inhibitorTERNS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1868US2021379043A1Combination treatment of liver disordersTERNS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1968US2026015348A1Compounds as glp-1r agonistsTERNS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2067US2022348561A1Thyroid hormone receptor beta agonist compoundsTERNS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2165US2024398794A1COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOFTERNS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2264US2025090530A1Combinations for the treatment of cancerTERNS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2363US2024368120A1Compounds as glp-1r agonistsTERNS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2463US2022089578A1Compounds as glp-1r agonistsTERNS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2563US2023322744A1Compounds as glp-1r agonistsTERNS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2662US2024293416A1TREATMENT OF LIVER DISORDERS WITH A THR-ß AGONISTTERNS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2762US2023241071A1Combination treatment of liver disordersTERNS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2856US2024116912A1Compounds and methods for modulating fxrTERNS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2956US2024059682A1Thyroid hormone receptor beta agonist compoundsTERNS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3054US12528791B2Thyroid hormone receptor beta agonist compoundsTERNS PHARMACEUTICALS INC·Filed 2020·Granted Jan 20, 2026·0 cites·33 claims
- 3154US12485118B2Combinations of GLP-1R and THRβ agonists and methods of use thereofTERNS PHARMACEUTICALS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 3254US2021379040A1Combination treatment of liver disordersTERNS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3351US12398127B2Thyroid hormone receptor beta agonist compoundsTERNS PHARMACEUTICALS INC·Filed 2020·Granted Aug 26, 2025·0 cites·19 claims
- 3451US2022387414A1Treating liver disordersTERNS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3550US2022362245A1Compounds for inhibiting fgfr4TERNS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3648US2021244744A1Treating liver disordersTERNS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →